Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human T cells and hematopoietic stem and progenitor cells using base editing.

Gene Editing / methods HIV Infections / genetics HIV-1 / physiology Hematopoietic Stem Cells / metabolism Humans Receptors, CCR5 / genetics Receptors, CXCR4 / genetics T-Lymphocytes / metabolism
Base editing CCR5 CRISPR/Cas9 CXCR4 HIV HSC

Journal

Molecular therapy : the journal of the American Society of Gene Therapy
ISSN: 1525-0024
Titre abrégé: Mol Ther
Pays: United States
ID NLM: 100890581

Informations de publication

Date de publication:
05 01 2022
Historique:
received: 25 02 2021
revised: 31 08 2021
accepted: 27 10 2021
pubmed: 6 11 2021
medline: 8 4 2022
entrez: 5 11 2021
Statut: ppublish

Résumé

Disruption of CCR5 or CXCR4, the main human immunodeficiency virus type 1 (HIV-1) co-receptors, has been shown to protect primary human CD4

Identifiants

DOI: 10.1016/j.ymthe.2021.10.026 PMID: 34737067 PMC: PMC8753564
pubmed: 34737067
pii: S1525-0016(21)00570-0
doi: 10.1016/j.ymthe.2021.10.026
pmc: PMC8753564
pii:
doi:

Substances chimiques

CCR5 protein, human 0
CXCR4 protein, human 0
Receptors, CCR5 0
Receptors, CXCR4 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

130-144

Subventions

Organisme : NCI NIH HHS
ID : P01 CA065493
Pays : United States
Organisme : NHGRI NIH HHS
ID : RM1 HG009490
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM118062
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI142756
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB022376
Pays : United States
Organisme : NIDDK NIH HHS
ID : U54 DK106829
Pays : United States

Informations de copyright

Copyright © 2021 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests D.R.L. is a consultant and equity owner of Beam Therapeutics, Prime Medicine, and Pairwise Plants, companies that use genome editing. D.R.L. and G.A.N. have filed patent applications relating to the use of genome editors. T.I.C. has sponsored research collaboration with Cellectis and Miltenyi Biotec. The remaining authors declare no competing interests. A.M. is a scientific advisory board member at mCureX Therapeutics, Inc., an mRNA company and a consultant for TriLink BioTechnologies.

Références

Arthritis Res Ther. 2010;12(5):R188
pubmed: 20939892
Nat Biotechnol. 2020 Apr;38(4):471-481
pubmed: 32042170
Science. 1999 Feb 5;283(5403):845-8
pubmed: 9933168
Nat Methods. 2017 Jun;14(6):607-614
pubmed: 28459458
Nature. 1996 Aug 29;382(6594):829-33
pubmed: 8752280
Curr Protoc. 2021 Feb;1(2):e39
pubmed: 33524237
Nat Med. 2020 Apr;26(4):535-541
pubmed: 32284612
N Engl J Med. 2014 Mar 6;370(10):901-10
pubmed: 24597865
Nat Commun. 2019 Nov 19;10(1):5222
pubmed: 31745080
Nat Methods. 2017 Jul;14(7):710-712
pubmed: 28581493
PLoS Pathog. 2016 Nov 17;12(11):e1005983
pubmed: 27855210
Mol Ther Methods Clin Dev. 2020 Jul 15;18:679-691
pubmed: 32802914
Nature. 2020 Jul;583(7817):631-637
pubmed: 32641830
Nucleic Acids Res. 2013 Nov;41(20):9584-92
pubmed: 23939622
Nat Biotechnol. 2020 May;38(5):620-628
pubmed: 32042165
N Engl J Med. 2009 Feb 12;360(7):692-8
pubmed: 19213682
Nucleic Acids Res. 2015 Jun 23;43(11):5560-71
pubmed: 25964300
Sci Adv. 2017 Aug 30;3(8):eaao4774
pubmed: 28875174
Mol Biol Cell. 2018 Jan 15;29(2):75-83
pubmed: 29167381
Hum Gene Ther. 2018 Jan;29(1):51-67
pubmed: 28599597
J Virol. 1998 Mar;72(3):2002-9
pubmed: 9499054
Mol Ther. 2020 Feb 5;28(2):431-440
pubmed: 31843453
Cells. 2020 Jul 10;9(7):
pubmed: 32664329
J Immunol. 1999 Sep 1;163(5):2368-72
pubmed: 10452968
Nat Protoc. 2018 Nov;13(11):2615-2642
pubmed: 30341435
Blood. 2014 Jan 2;123(1):61-9
pubmed: 24162716
Nat Biotechnol. 2008 Jul;26(7):808-16
pubmed: 18587387
Mol Ther Nucleic Acids. 2016 Aug 23;5(8):e352
pubmed: 27741222
J Virol. 1995 Jun;69(6):3712-20
pubmed: 7745720
Clin Transl Med. 2020 Feb 7;9(1):15
pubmed: 32034584
J Virol. 1990 May;64(5):2337-44
pubmed: 2182911
Nat Biotechnol. 2020 Jul;38(7):824-844
pubmed: 32572269
Nat Biotechnol. 2018 Sep;36(8):765-771
pubmed: 30010673
Nat Biotechnol. 2018 Oct;36(9):843-846
pubmed: 29813047
Science. 2018 Sep 21;361(6408):1259-1262
pubmed: 30166441
Nature. 2019 May;569(7756):433-437
pubmed: 30995674
Genome Biol. 2018 Dec 22;19(1):226
pubmed: 30577870
Lancet HIV. 2020 May;7(5):e340-e347
pubmed: 32169158
Nat Biotechnol. 2019 Apr;37(4):430-435
pubmed: 30833658
Nat Biotechnol. 2010 Aug;28(8):839-47
pubmed: 20601939
Sci Adv. 2019 May 08;5(5):eaax5717
pubmed: 31086823
Nature. 2017 Nov 23;551(7681):464-471
pubmed: 29160308
Nat Commun. 2017 Jun 06;8:15790
pubmed: 28585549
Nat Biotechnol. 2019 Sep;37(9):1070-1079
pubmed: 31332326
N Engl J Med. 2019 Sep 26;381(13):1240-1247
pubmed: 31509667
Biotechnol J. 2021 Jan;16(1):e2000023
pubmed: 33103367
Cell. 1996 Aug 9;86(3):367-77
pubmed: 8756719
Virology. 1992 Jul;189(1):167-77
pubmed: 1604808
Cell Biosci. 2017 Sep 9;7:47
pubmed: 28904745
J Clin Invest. 2021 Apr 1;131(7):
pubmed: 33571163
J Exp Med. 1997 Feb 17;185(4):621-8
pubmed: 9034141
J Virol. 2014 May;88(9):4976-86
pubmed: 24554663
Mol Ther. 2017 Aug 2;25(8):1782-1789
pubmed: 28527722
Nat Biotechnol. 2011 Aug 07;29(9):816-23
pubmed: 21822255
Nat Biotechnol. 2020 Jul;38(7):883-891
pubmed: 32433547
Nat Biotechnol. 2019 Mar;37(3):224-226
pubmed: 30809026
Nature. 2016 Apr 20;533(7603):420-4
pubmed: 27096365
Nat Biotechnol. 2015 Feb;33(2):179-86
pubmed: 25503383
Nat Rev Genet. 2018 Dec;19(12):770-788
pubmed: 30323312
Biochem Biophys Res Commun. 2015 Oct 9;466(1):89-94
pubmed: 26321665
J Exp Med. 2006 Jan 23;203(1):35-40
pubmed: 16418398
Nat Med. 2018 Jul;24(7):927-930
pubmed: 29892067
Mol Ther Methods Clin Dev. 2016 Nov 09;3:16067
pubmed: 27900346
J Infect Dis. 2000 Mar;181(3):927-32
pubmed: 10720514
Nature. 2019 Apr;568(7751):244-248
pubmed: 30836379
Mol Cell. 2017 Sep 21;67(6):1068-1079.e4
pubmed: 28890334
Nat Biotechnol. 2017 May;35(5):475-480
pubmed: 28398345
J Exp Med. 1997 Jan 6;185(1):111-20
pubmed: 8996247
Nature. 1996 Jun 20;381(6584):667-73
pubmed: 8649512
Mol Ther. 2013 Jun;21(6):1259-69
pubmed: 23587921
Lancet HIV. 2015 Jun;2(6):e236-42
pubmed: 26423196
Science. 1997 Apr 4;276(5309):51-2
pubmed: 9122710
Mol Ther Nucleic Acids. 2018 Sep 7;12:530-542
pubmed: 30195789

Auteurs

Friederike Knipping (F)

Medical School, Department of Pediatrics, Division of Blood and Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA.

Gregory A Newby (GA)

Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA; Howard Hughes Medical Institute, Harvard University, Cambridge, MA 02138, USA.

Cindy R Eide (CR)

Medical School, Department of Pediatrics, Division of Blood and Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA.

Amber N McElroy (AN)

Medical School, Department of Pediatrics, Division of Blood and Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA.

Sarah C Nielsen (SC)

Medical School, Department of Pediatrics, Division of Blood and Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA.

Kyle Smith (K)

Medical School, Department of Pediatrics, Division of Blood and Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA.

Yongxing Fang (Y)

Institute for Transfusion Medicine and Gene Therapy, Medical Center, University of Freiburg, Freiburg 79106, Germany; Center for Chronic Immunodeficiency, Medical Center, University of Freiburg, Freiburg 79106, Germany; MD Program, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.

Tatjana I Cornu (TI)

Institute for Transfusion Medicine and Gene Therapy, Medical Center, University of Freiburg, Freiburg 79106, Germany; Center for Chronic Immunodeficiency, Medical Center, University of Freiburg, Freiburg 79106, Germany; Faculty of Medicine, University of Freiburg 79106, Germany.

Caroline Costa (C)

CIRI - International Center for Infectiology Research, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon, F-69007 Lyon, France.

Alejandra Gutierrez-Guerrero (A)

CIRI - International Center for Infectiology Research, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon, F-69007 Lyon, France.

Samuel P Bingea (SP)

Medical School, Department of Pediatrics, Division of Blood and Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA.

Colby J Feser (CJ)

Medical School, Department of Pediatrics, Division of Blood and Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA.

Benjamin Steinbeck (B)

Medical School, Department of Pediatrics, Division of Blood and Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA.

Keli L Hippen (KL)

Medical School, Department of Pediatrics, Division of Blood and Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA.

Bruce R Blazar (BR)

Medical School, Department of Pediatrics, Division of Blood and Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA.

Anton McCaffrey (A)

TriLink BioTechnologies, San Diego, CA 92121, USA.

Claudio Mussolino (C)

Institute for Transfusion Medicine and Gene Therapy, Medical Center, University of Freiburg, Freiburg 79106, Germany; Center for Chronic Immunodeficiency, Medical Center, University of Freiburg, Freiburg 79106, Germany; Faculty of Medicine, University of Freiburg 79106, Germany.

Els Verhoeyen (E)

CIRI - International Center for Infectiology Research, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon, F-69007 Lyon, France; Université Côte d'Azur, INSERM, C3M, 06204 Nice, France.

Jakub Tolar (J)

Medical School, Department of Pediatrics, Division of Blood and Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA.

David R Liu (DR)

Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA; Howard Hughes Medical Institute, Harvard University, Cambridge, MA 02138, USA.

Mark J Osborn (MJ)

Medical School, Department of Pediatrics, Division of Blood and Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA. Electronic address: osbor026@umn.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Génie génétique › Édition de gène › Disruption of HIV-1 co-receptors CCR5 and...
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › Disruption of HIV-1 co-receptors CCR5 and...
questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Lentivirus › Lentivirus des primates › VIH (Virus de l'Immunodéficience Humaine) › VIH-1 (Virus de l'Immunodéficience Humaine de type 1) › Disruption of HIV-1 co-receptors CCR5 and...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système hématopoïétique › Cellules de la moelle osseuse › Cellules souches hématopoïétiques › Disruption of HIV-1 co-receptors CCR5 and...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Disruption of HIV-1 co-receptors CCR5 and...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs viraux › Récepteur VIH › Récepteurs CCR5 › Disruption of HIV-1 co-receptors CCR5 and...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs viraux › Récepteur VIH › Récepteurs CXCR4 › Disruption of HIV-1 co-receptors CCR5 and...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Disruption of HIV-1 co-receptors CCR5 and...